Kymera Therapeutics Begins U.S. IPO Effort

8/6/20

By Donovan Jones, SeekingAlpha

Kymera Therapeutics (KYTX) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.

The firm is a preclinical biopharma, researching treatments for various skin disorders and immune conditions.

While KYTX is still at a very early stage, the firm has impressive collaborations and investor partners.

I'll provide a final opinion when we learn more about the IPO.

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.